Another retrospective research showed that SII predicts prognosis and neoadjuvant chemotherapy efficacy in patients with Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer [25]. The gene discussed is ERBB2; the disease is breast carcinoma.